GlassScriptPhysician profile
Ked L Davis
NPI 1699981894
$3,343.06
in general payments reported to CMS, 2019-2025
33 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $746 · 2021: $635 · 2022: $489 · 2023: $502 · 2024: $221 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.24 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $348.43 | 2019-2025 | Trintellix |
| Pfizer INC. | $282.56 | 2019-2025 | |
| Novo Nordisk INC | $268.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $248.60 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $236.28 | 2019-2023 | |
| Lilly USA, LLC | $223.71 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $211.78 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $101.41 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.58 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $91.50 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $86.18 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.33 | 2022-2023 | |
| Exact Sciences Corporation | $72.46 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $57.30 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $53.25 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $47.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.25 | 2019-2020 | |
| Genentech USA, INC. | $44.24 | 2020-2021 | |
| Allergan, INC. | $35.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.46 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $28.04 | 2023 | |
| Dexcom, INC. | $27.79 | 2022-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $26.39 | 2019-2023 | Eliquis |
| Mylan Specialty L.P. | $19.21 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $18.39 | 2019 | |
| Eisai INC. | $15.61 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.59 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.57 | 2022 | |
| Axsome Therapeutics, INC. | $14.54 | 2025 | Auvelity |
| Amarin Pharma, INC. | $12.34 | 2020 | |
| Biodelivery Sciences International, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ked Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.